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Background: Novel molecules that specifically target human TNFα in rheumatoid arthritis pose problems for
preclinical assessment of efficacy. In this study collagen antibody-induced arthritis (CAIA) has been induced in
human TNFα transgenic mice to provide a novel model that has been optimised for the evaluation of molecules
targeting human TNFα.
Methods: Tg1278TNFko mice lack murine TNFα and are heterozygous for multiple copies of the human TNFα
transgene that is expressed under normal physiological control. To establish CAIA, a collagen II monoclonal
antibody cocktail (CAb) at 2, 4 or 8 mg was injected i.p. on Day 0 followed by a lipopolysaccharide (LPS) boost
(10 or 100 μg) i.p. on Day 1 or Day 4. Animals were assessed for arthritis symptoms using a clinical score, cytokine
levels (human TNFα, IL-1β and IL-6) in sera and joints, and histopathology. The dependence of the model on
human TNFα was determined by dosing animals with etanercept.
Results: Tg1278TNFko animals treated with 2, 4 or 8 mg CAb on Day 0, with 100μg LPS on Day 4, had more severe
arthritis and earlier symptoms than wild type animals at all doses of CAb tested. Subsequently it was found that the
transgenic model did not require LPS at all for arthritis development but a lower dose of LPS (10 μg) was found
necessary for reproducible and robust disease (close to 100% incidence, well-synchronised, with high arthritis
scores). Furthermore the LPS challenge could be brought forward to Day 1 so that its’ actions to facilitate disease
could be separated temporally from the arthritis phase (beginning about Day 4). Etanercept, administered immediately
after the serum spike of cytokines associated with LPS had subsided, was able to dose-dependently inhibit arthritis
development and this was associated with a marked protection of the joints histologically on Day 14. Etanercept was
also able to reverse the signs of arthritis when given therapeutically allowing animals to be matched for disease burden
before dosing begins.
Conclusions: The features of CAIA in Tg1278TNFko animals make the model well-suited to testing the next generation
of therapeutics that will target human TNFα in rheumatoid arthritis.
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In recent years the treatment of rheumatoid arthritis
(RA) has been transformed by the development of bio-
logics targeting tumour necrosis factor alpha (TNFα).
Response rates to treatment, as assessed by American
College of Rheumatology (ACR) criteria, are typically in
the region of 60% ACR20, 40% ACR50 and 20% ACR70
at 24 weeks of treatment [1]. However biologics are ex-
pensive and so are not as widely used as they might be.
Typically patients will have failed conventional treat-
ments such as methotrexate before being considered suit-
able for anti TNFα therapy. The problem with this is that
anti TNFα treatment might be more effective if initiated
early, and indeed current thinking is to identify and treat
RA patients as quickly as possible in an attempt to induce
long term remission [2]. Another problem with biologics
is that they are inconvenient to administer when com-
pared with conventional therapy.
One view of biological agents directed towards TNFα
is that they have validated TNFα as a target for the
treatment of RA but that they will be superseded by
small molecules that act on the same pathway. These
treatments may be cheaper, more convenient to admin-
ister and suitable as first line therapy either alone or in
combination with other anti-rheumatic drugs such as
methotrexate.
Despite the success of anti TNFs in the treatment of
RA, most of the preclinical work directed against TNFα
was to support sepsis as a disease indication [3]. Unfor-
tunately anti TNFs proved to be a spectacular failure in
sepsis. However, subsequent work in the human TNFα
Tg197 transgenic mouse model of arthritis supported
the therapeutic potential of anti-human TNFα in RA [4]
that was later confirmed by a small trial in RA [5]. It is in-
teresting to speculate on whether anti TNFs would ever
have reached the clinic for RA if preclinical development
had been through conventional models such as collagen
induced arthritis (CIA) in rodents. Targeting TNFα, al-
though effective to some extent in CIA, is rather less ac-
tive than targeting IL-1β [6,7] which is actually the reverse
of the clinical findings. CIA is also time consuming and
suffers from variable incidence and severity. So CIA can-
not be considered an ideal model for the testing of the
next generation of TNFα inhibitors.
Because TNFα is an “effector cytokine”, playing a role in
inflammation and joint destruction, a short term model
that avoids the need for immune sensitization but estab-
lishes a role for TNFα in an inflammatory arthritis should
offer advantages over CIA. One such model is the collagen
II antibody induced arthritis (CAIA) model [8] (the K/
BxN serum transfer model is another [9]). These models
tend to be more robust than CIA and have been shown
to have a TNFα component [10,11]. However, species
differences between mice and human are a problemfor biologics and potentially also for small molecules
depending upon their mode of action.
Transgenic technology can help here. The Tg197 mouse
is a human TNFα transgenic mouse that over expresses
TNFα [4]. These animals develop spontaneous and pro-
gressive arthritis from about 3 weeks of age demonstrating
that pathology associated with TNFα in RA can be reca-
pitulated in the mouse. However, although the model has
been used with success for the preclinical profiling of bio-
logics that target human TNFα [12] there are some draw-
backs. The animals are sick from an early age, and the
chronicity of the model (up to 7 weeks) has implications
for compound requirements particularly if dosing needs
to be once or twice a day.
Another transgenic model is the Tg1278 mouse [4]. The
Tg1278 contains ~50 copies of a 3.6 kb DNA fragment
comprising the entire human TNFα coding sequences
flanked by its own 5′ and 3′ regulatory sequences. The
Tg1278 has been crossed to TNFα knock-out mice, result-
ing in a mouse strain (Tg1278TNFko) with normally regu-
lated and expressed human TNFα in the absence of
mouse TNFα. The human TNFα partially compensates for
defects in lymphoid architecture seen in TNFα knockout
mice [13] and the animals are healthy and do not develop
spontaneous disease. The aim of this study was to charac-
terise CAIA in these animals as a potential new model for
investigating novel treatments targeting TNFα in RA.
Materials and methods
Materials
Arthritomab collagen II antibody cocktail (CAb)(Cat: CIA-
MAB-2C, LOT: S1109002) and lipopolysaccharide (LPS) E.
coli (055:B5, LOT: 20318A4) were from MDbioscience.
Etanercept (Enbrel®) was from Pfizer.
Animals
Mice were housed in specific pathogen free conditions
with 3–4 animals per cage of 335 cm2 (Techniplast, UK)
on a dust free plant fibre bedding (TierWohl, Germany)
and maintained at 21-24°C, 55-65% humidity, 10–12 air
changes per hour and on a 12 hour light dark cycle. Ani-
mals had access to a standard maintenance diet (1324
Diet-Rats/Mice, Altromin, Germany) and water ad libitum.
Wild type C57BL/6J mice were obtained from Charles
River Laboratories. To generate Tg1278TNFko animals,
male stud mice heterozygous for Tg1278 and homozy-
gous for TNFko (maintained in a C57BL/6 genetic back-
ground) were crossed with TNFko C57BL6 females. Their
Tg1278TNFko heterozygous transgenic offspring were
identified by tail DNA genotyping. Groups were matched
as closely as possible for mean body weights. Male and
female animals were used as indicated.
Experiments were conducted at Biomedcode and
conformed with the Presidential Decree No 160/1991
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which is the implementation of the EEC Directive 86/609/
EEC. Protocols were reviewed and approved by the
Institutional Animal Ethical Committee at the Biomedical
Sciences Research Centre “Al. Fleming”.
CAIA induction
Mice were injected with CAb intraperitoneally (i.p.) at 2-
8 mg per mouse as indicated. Where LPS was adminis-
tered this was either Day 1 or Day 4 at 10 or 100 μg i.p.
per animal. Blood samples were collected at indicated
times from retro-orbital bleeds using heparin coated glass
capillaries. Serum was prepared and stored at −70°C prior
to analysis. Clinical development of arthritis in the paws
was assessed by arthritis score, 0 normal, 1 erythema and
mild swelling confined to the tarsals or ankle joint, 2 ery-
thema and mild swelling extending from the ankle to the
tarsals, 3 erythema and moderate swelling extending from
the ankle to metatarsal joints, 4 erythema and severe
swelling encompass the ankle, foot and digits, or ankylosis
of the limb. Thus the maximum score an animal could at-
tain was 16.
Dosing
Animals were dosed with etanercept where indicated.
The drug was diluted with sterile saline and adminis-
tered at 10 mL/kg intravenously (i.v.) for the first dose
and subcutaneously (s.c.) for subsequent doses. Sterile
saline served as a vehicle control.
Cytokine assays
Cytokine measurements were made on serum samples
and paws of CAIA animals. Paws were dissected above
ankle at different time points post LPS challenge. One
hind paw per animal was used for protein extraction.
Collected paws were crushed in liquid nitrogen using a
pulverizer and the tissue amount obtained from each
paw was weighed. 1.5 mL of tissue extraction buffer (Life
technologies), containing phosphatase inhibitor cocktail
(Roche, 1 tablet 10 mL of extract) and protease inhibi-
tors cocktail set IV (1:100 dilution, Merck), were used
per sample. Samples were vortexed and then centrifuged
at 4°C 2100 rpm for 10 minutes (IEC Centra GP8R) to
pellet the tissue debris and supernatants re-centrifuged
at 4°C 2000 rpm for 15 minutes. Supernatants were col-
lected and total protein concentration in samples was
measured using the microplate procedure for BCA assay
(Thermo Scientific) according to the manufacturer’s in-
structions and absorbance was determine using the BCA
assay setting on a NanoDrop (extraction solution was
used as a blank). All samples were stored at −80°C prior
to cytokine assay. Human TNFα cytokine ultra-sensitive
kit (MSD, Meso Scale Discovery), mouse IL-17 cytokine
ultra-sensitive kit (MSD, Meso Scale Discovery) andmouse proinflammatory 7-plex ultra-sensitive assay de-
tecting IL-1β, IL-10, Il-12p70, INF-ɣ, IL-6, KC, TNFα
(MSD, Meso Scale Discovery) were used to measure cyto-
kine concentration in serum and protein extracts. The
MSDs were used according to manufacturer protocols.
Histopathological examination
Mouse paws were harvested, fixed in 10% neutral-buffered
formalin, decalcified in 10% formic acid for 4 days, embed-
ded in paraffin, sectioned, and stained with either haema-
toxylin & eosin for general evaluation or toluidine blue for
specific assessment of cartilage changes. The stained slides
were scanned on a whole slide scanner (Nanozoomer 2.0-
HT, Hamamatsu, Japan) to acquire whole slide imaging
at × 20 magnification.
Statistical analysis
GraphPad Prism software was used to analyse all data.
The in vivo arthritis score data were calculated as area
under curve. These data and the cytokine data were ana-
lysed by one-way analysis of variance (ANOVA) with
Bonferroni post-test.
Results
Figure 1 shows arthritis score data and bodyweight data
for wild type and Tg1278TNFko animals following in-
duction of collagen antibody induced arthritis with 2, 4
or 8 mg CAb administered i.p. and 100 μg LPS adminis-
tered i.p. 4 days later according to the manufacturer’s in-
structions. Incidence of arthritis in all groups was 100%,
however, in wild type animals the severity of the arthritis
was considerably lower than in the Tg1278TNFko ani-
mals for all doses of CAb administered.
LPS challenge was associated with weight loss that was
evident from time of challenge (Day 4) to Day 6 when
weights were next recorded. For wild type animals the
weight loss amounted to approximately 16% but it was
rather higher in the Tg1278TNFko animals at approxi-
mately 22%. Although bodyweights recovered as expected,
the general condition of the Tg1278TNFko animals was a
cause for concern throughout the experiment. A study
was therefore conducted to see if a lower LPS challenge
could be used in the Tg1278TNFko animals.
The results of a 10 μg challenge of LPS on Day 4 are
shown in Figure 2. Arthritis incidence was again 100%
across all the groups. Arthritis score data were comparable
for the 2 mg and 4 mg CAb groups but were rather lower
than achieved for the same doses in the first experiment
where a higher LPS challenge was used. However, the 8 mg
CAb group showed robust disease. Weight loss for all
groups between days 4 and 6 was approximately 15% be-
fore recovering and the overall condition of the animals
was improved over the first experiment.




























































































Figure 1 CAIA in wild type and Tg1278TNFko animals. Arthritis was induced in male mice by i.p. injection of 2, 4 or 8 mg collagen II antibody
cocktail (CAb) on Day 0 followed by 100 μg LPS i.p. 4 days later. A, Arthritis scores of wild type animals. B, arthritis scores of Tg1278TNFko animals.
C, Bodyweights of wild type animals. D, bodyweights of Tg1278TNFko animals. Data are means +/− s.e.m., n = 6-8/group.
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arthritis before LPS challenge. This prompted an add-
itional study where a group of animals were injected
with 8 mg CAb and arthritis development followed over
time without LPS challenge (Figure 2C). Once again in-
cidence of arthritis was 100% but there was rather more
variability in the data. As expected, bodyweights were
maintained over the experiment (Figure 2D).
Although the study without LPS indicated that LPS
was not necessary for induction of arthritis, it did appear
to improve synchronization and severity of the disease
and open up a good window for TNFα inhibitor studies.
So we investigated whether the LPS challenge could be
brought forward to a time before arthritis symptoms be-
came manifest so that TNFα production associated with
LPS challenge could be differentiated from TNFα that
may be driving the arthritis.
We therefore measured temporal cytokine profiles in
sera or joints of animals where LPS challenge was admin-
istered just 1 day after 8 mg CAb (Figure 3). When cyto-
kines were measured in serum there was an expected
acute rise in serum hTNFα following LPS challenge andthis was followed by rises in IL-1β and IL-6 (Figure 3A, C
and E). By 24 hours post LPS, serum cytokines were drop-
ping back to baseline levels. There was no sign of a subse-
quent increase in serum cytokine levels coincident with the
emergence of arthritis symptoms. Indeed, and rather curi-
ously, there was a drop in serum IL-1β at days 3, 5 and 13
post LPS perhaps reflecting a recruitment of IL-1β secret-
ing cells to inflamed joints (although similar reductions
were not seen in circulating hTNFα or IL-6). The data
for the paws were clearly biphasic with acute elevations
in cytokines following LPS injection and then elevations
at days 5 and 13 associated with the arthritis phase of
the model (Figure 3B, D and F). These data indicated that
cytokine release post LPS could be separated from cyto-
kines associated with arthritis and in subsequent studies
LPS was always administered on Day 1. This system was
also used to examine the effects of the TNFα blocker
etanercept.
The profile of arthritis in the Day 1 LPS challenge
model was comparable to the Day 4 LPS challenge
model (Figure 4A compared with Figure 2A). Other
groups were dosed with etanercept at 0.3, 3 or 30 mg/kg























































































Figure 2 CAIA in Tg1278TNFko animals in the presence or absence of LPS challenge. Arthritis was induced in male mice by i.p. injection of
2, 4 or 8 mg collagen II antibody cocktail (CAb) on Day 0. The effects of administering 10 μg LPS i.p. 4 days later on arthritis scores are shown in
A, and on bodyweights in B. C, shows arthritis scores in the absence of LPS challenge and D shows effects on bodyweight. Data are means +/− s.e.m.,
n = 5-7/group.
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the transient TNFα spike associated with LPS challenge.
The first doses were all i.v. to achieve rapid exposure to
the drug and subsequent doses were s.c.. Again arthritis
incidence was 100% although 2 of the 8 animals in the
vehicle control group had a poor disease severity. The
results are broken down further into individual animals
in Figure 4B where it can be seen that both animals with
mild disease were females. Nonetheless there were dose-
dependent decreases in arthritis scores with etanercept
treatment with 3 and 30 mg/kg treatments resulting in
statistically significant reductions in arthritis scores com-
pared with the vehicle-treated controls (p < 0.05 and p <
0.01) respectively.
Joints were removed from arthritic animals on Day 14
and compared with normal joints and joints from arth-
ritic animals that had been dosed with etanercept at 30
mg/kg i.v. 6 hours post LPS and every other day s.c.
thereafter. In comparison with normal joints (Figure 5A
and B) arthritic animals showed synovial hyperplasia, in-
flux of inflammatory cells and erosion of cartilage andbone (Figure 5C and D). In etanercept-treated mice there
was only mild inflammatory cell influx and no obvious
destruction of cartilage and bone (Figure 5E and F).
Finally, the effect of dosing with etanercept was inves-
tigated at various times post LPS challenge (Figure 4C).
Arthritis incidence in the controls was again 100% and
the variability was less than in the previous experiment.
However, when the data were broken down for individual
animals it can be seen that the three lowest scoring ani-
mals in the vehicle control group were females (Figure 4D).
Etanercept treatment at 30 mg/kg either 6 hours, 2 days
or 4 days after LPS resulted in statistically significant re-
ductions in arthritis scores compared with vehicle-treated
controls (p < 0.001, p < 0.001 and p < 0.05 respectively).
Discussion
CAIA in wild type mice is a B and T cell independent
model of arthritis [13]. The main effector cells appear to
be neutrophils and macrophages [14,15] that are activated
by immune complexes that are formed in the joints by the
binding of collagen II antibodies to the cartilage surfaces.
Figure 3 Cytokines in serum and paws of Tg1278TNFko animals with CAIA. Arthritis was induced in male and female mice by i.p. injection
of 8 mg collagen II antibody cocktail (CAb) on Day 0 followed by 10 μg LPS i.p. 1 day later. Open bars are data for sera and closed bars are data
for paws (expressed as pg cytokine/mg protein). A and B hTNFα, C and D IL-1β, E and F IL-6. Data are means +/− s.e.m., n = 3-4/group. *p < 0.05,
***p < 0.001 comparison with time 0.
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Figure 4 Effects of etanercept on CAIA in Tg1278TNFko animals. Arthritis was induced in male and female mice by i.p. injection of 8 mg
collagen II antibody cocktail (CAb) on Day 0 followed by 10 μg LPS i.p. 1 day later. A shows the effects of dosing etanercept at 0.03, 0.3, 3 or
30 mg/kg i.v. for the first dose with subsequent doses s.c. from 6 hours post LPS administration with individual animal data expressed as area
under curve (AUC) arthritis score shown in B. C, shows the effects of etanercept dosing at 30 mg/kg from 6 hours, 2 days or 4 days post LPS with
individual animal data shown in D. Data are means +/− s.e.m., n = 8/group. *p < 0.05, **p < 0.01, ***p < 0.001 comparison with the vehicle
control group.
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activation, particularly activation through the alternative
pathway [15,17]. Many of the pathological changes that
are typical of RA can be seen in the joints of animals with
CAIA such as synovitis, pannus formation and destruction
of cartilage and bone [18,19]. The model is quick, as it
requires no immune priming, and it can be performed
in a variety of mouse strains including knock outs and,
as here, transgenic animals. Disease onset is well-
synchronized but severity of disease varies with strain
and protocol [20]. The model has value for investigat-
ing effector mechanisms of arthritis and for assessing
novel therapeutic agents that work on the effector stage
of the disease.
The inclusion of LPS into the CAIA protocol improves
disease severity but is not necessarily essential to disease
induction [21]. The role that LPS plays is unclear and it
probably works through multiple mechanisms that are
downstream of TLR4 activation. One possibility is thatin the absence of LPS, insufficient collagen II antibody is
able to access the joints to promote a maximal inflam-
matory response and that LPS simply increases antibody
access by increasing vascular permeability. But whatever
the mechanism, the effects of LPS are transient, and
whilst LPS may facilitate the disease process, it is not it-
self a part of it. For this reason it is important that po-
tential anti-arthritic drugs should be dosed subsequent
to LPS challenge because otherwise interference with
LPS biology may erroneously be interpreted as an anti-
arthritic effect.
In the current set of experiments we compared the
standard CAIA model in wild type C57Bl/6 mice with
CAIA induced in Tg1278TNFko mice with a view to de-
veloping an arthritis model that is dependent upon human
TNF for the evaluation of novel therapeutic entities. The
Tg1278TNFko mouse is attractive for studying human
TNFα biology as TNFα production is under physiological
control [4] and the animals are perfectly healthy in normal
Figure 5 Histology of fore paws from CAIA in Tg1278TNFko animals. Arthritis was induced by i.p. injection of 8mg collagen II antibody
cocktail (CAb) on Day 0 and 10μg LPS i.p. 1 day later. Joints were taken on Day 14. A, C and E, haematoxylin and eosin, B, D and F, toluidine
blue. Compared with normal paws (A and B), arthritic paws (C and D) show infiltration with inflammatory cells and erosion of cartilage and
bone. The effect of treating with etanercept at 30mg/kg is shown in e and f. Inflammatory cell influx is reduced and there is no cartilage or
bone erosion.
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mechanism of CAIA induction in Tg1278TNFko animals
is fundamentally different to wild type animals. However,the replacement of the murine TNFα gene with multiple
copy numbers of the human TNFα gene results in approxi-
mately 100 fold higher levels of LPS-induced TNFα than
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and the fact that human TNFα will only signal through
murine TNFR1 and not TNFR2 [22], suggests that inflam-
matory TNFα biology will be accentuated. This probably
explains why in our hands arthritis was more severe in the
Tg1278TNFko animals than in wild type animals when an
identical protocol for arthritis induction was used.
Although the protocol used to establish arthritis in
wild type animals induced a more severe arthritis in
Tg1278TNFko animals, the Tg1278TNFko animals did
not tolerate the dose of LPS well. Weight loss was more
marked than in wild type animals and even after body-
weights had started to recover the general condition of
the animals was a matter for concern that required more
frequent monitoring. However, it was found that the
LPS challenge dose could be reduced by a factor of 10,
to 10 μg, and Tg1278TNFko animals would still develop
robust arthritis at the highest dose of CAb that was ad-
ministered (8 mg) and that the lower LPS dose was well-
tolerated. In this experiment it was also noticed that all
animals in the 8 mg dose group showed signs of arthritis
prior to LPS challenge. It was therefore of interest to
conduct a study without LPS to examine the severity
and variability of the arthritis.
A CAIA model without LPS would in fact have been
the preferred model to develop but even although inci-
dence of arthritis was again 100% the severity was low
and the variability high. Whether more severe disease
with less variability would be possible at higher doses of
CAb is unclear but cost of the antibody cocktail, and
amount of material required, make this impractical to
follow up. Another possibility for an LPS-free model
might be to increase the number of antibodies in the
cocktail that see different collagen II epitopes, as this
has been reported to increase disease severity in wild
type animals [23].
Accepting that LPS challenge would be a requirement
for this model we next sought to introduce the challenge
earlier in the protocol i.e. one day after administration of
antibody cocktail and before any signs of arthritis were
manifest. This resulted in robust disease with one con-
trol animal showing a maximal score. When inflamma-
tory cytokines were measured in the serum there was an
acute rise and fall following LPS challenge but no sign of
elevations in the arthritis phase of the model. By con-
trast, in the joints, a biphasic response was seen with el-
evations associated with the LPS challenge and then
subsequently with the arthritis itself.
The histology of joints removed on Day 14 indicated
that the arthritis induced in Tg1278TNFko was erosive
as has been described for CAIA in wild type animals
[18,19]. The normal joint architecture was lost, there
was substantial inflammatory cell influx into the synovial
tissue and there was destruction of cartilage and bone.A good disease window (together with low data vari-
ability and high reproducibility) is desirable in a model
that is to be used for inhibition studies but it is also im-
portant that the disease is not so aggressive that it is im-
possible to inhibit. Although the disease window is
defined by the natural history of the model itself, the
ability to quantify the disease process can be limiting. In
this respect the arthritis scoring system is not ideal for
grading therapeutic responses as it only allows scores be-
tween 0 and 4 for each paw. An extended scoring system
has been suggested where numbers of involved joints are
counted and assigned a score that extends from 0 to 15
for each paw [20]. However, this scoring system does not
address the severity of the involved joints, and given that
there will be high levels of antibody cocktail in the circula-
tion, and that the effects of LPS are systemic, it seems
likely that all joints have an equal chance of being affected
by disease and that the aim of treatment in the model de-
scribed here should therefore be to reduce severity of in-
volved joints rather than number of involved joints.
Responsiveness of the model to treatment with the
TNFα blocker etanercept was assessed. Treatment was
initiated 6 hours after LPS challenge when the release of
TNFα associated with LPS had subsided (Figure 3) and
before arthritis symptoms were manifest. Doses ranged
from 0.3-30 mg/kg with the first dose being administered
i.v. and subsequent doses s.c every other day. Reductions
in arthritis scores were dose-related and statistically sig-
nificant in the 3 and 30 mg/kg groups. Furthermore eta-
nercept treatment protected against histological changes
in the joints demonstrating the utility of the model for
assessing anti TNFα effects in an arthritis setting.
In a final experiment a high dose of etanercept (30
mg/kg) was dosed at various times post the LPS chal-
lenge. Dosing 6 hours after LPS was effective in prevent-
ing arthritis and confirmed the findings of the previous
study. Almost as effective was dosing etanercept from 2
days after LPS. Interestingly, dosing from 4 days after
LPS, when all animals were already showing signs of
arthritis, was able to reverse signs and symptoms indi-
cating that the model can be used for therapeutic dosing.
The data are entirely consistent with the view that arth-
ritis in this model is driven by human TNFα although
murine factors upstream or downstream of human
TNFα, or synergising with human TNFα, could also be
important.
Although the disease window in this model is good, and
statistically significant reductions in arthritis scores were
attained with TNFα blockade, there was still some vari-
ability in the control responses. Interestingly it was female
animals that were associated with the lowest disease
scores in these studies. Male mice have been described as
being more prone to CAIA previously but this sex differ-
ence is described as being lost after LPS treatment [20].
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here will become clearer with time but the negative im-
pact of variability can be addressed by adopting thera-
peutic dosing strategies where groups can be matched for
disease severity before dosing begins. A version of the
model that employs therapeutic dosing from Day 3 is now
in regular use. The arthritis control and etanercept-treated
control groups have been run on 5 separate occasions (at
the time of manuscript submission) and the responses
have proved highly reproducible between experiments.
Conclusion
These studies describe the optimization of the CAIA
model in Tg1278TNFko animals to allow the evaluation
of anti-human TNFα biologics and small molecules. The
main features of the model are that it is induced, that dis-
ease incidence appears to be close to 100%, arthritis scores
can reach the maximal level and the model is responsive to
TNFα blockade, even when the disease is well-established.
These features together make the model well-suited to
testing the next generation of therapeutics that will target
human TNFα in rheumatoid arthritis.
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